positions available now

Category Archives: Clinical Development

Relating to Clinical Development sector of the Life Sciences Industry

Alternatives to Bioequivalence Trials

Earlier this week, Dr Greg Pearce, one of our senior regulatory consultants, presented at the ARCS Melbourne education seminar. His topic was the science and practical application of in vitro alternatives to conventional bioavailability and bioequivalence (BABE) clinical trials in … Continue reading

Posted in Clinical Development, Life Sciences Industry, Regulatory Services | Tagged , , | Comments Off on Alternatives to Bioequivalence Trials

What treatment switching means to the future of clinical trials

More and more frequently, treatment switching is occurring in clinical trials, particularly in the area of oncology. Not surprisingly, patients are demanding to be switched (most commonly) from the control treatment arm of a trial to the experimental treatment or … Continue reading

Posted in Clinical Development, Life Sciences Industry | Tagged | Comments Off on What treatment switching means to the future of clinical trials

New FDA draft guidance risks ‘Confused Consent’

Clinical trials require researchers to ensure that each participant is fully aware of the details of the trial before they take part. The FDA’s recently released draft guidance for Institutional Review Boards (IRBs), clinical investigators and sponsors on Informed Consent … Continue reading

Posted in Clinical Development, E-Health/Technology, Life Sciences Industry | Tagged | Comments Off on New FDA draft guidance risks ‘Confused Consent’

clinical trial design – overcoming the odds

Drug development costs anywhere between $1-4 billion by the time costs of failed drug candidates are factored in. A new drug can take anywhere from 10-15 years to obtain approval for human use. 80-85% of compounds fail early phase clinical … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access | Tagged , , | Comments Off on clinical trial design – overcoming the odds

Disinvestment in health care: friend or foe?

The clinical trial that led Commercial Eyes Market Access Consultant, Bridie Murphy, into the world of health technology assessment is still in the spotlight five years on. In July, The Conversation featured an article that looked at this and other … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access, MSAC | Tagged , , , | Comments Off on Disinvestment in health care: friend or foe?

Senate Estimates point to possible MRFF clinical trial funding

News that the Government is interested in using disbursements from the A$20 billion Medical Research Future Fund (MRFF) to invest in clinical trials is positive for the Australian life sciences R&D sector. There has been extensive speculation about whether the … Continue reading

Posted in Clinical Development, Federal Budget, Life Sciences Industry | Tagged , , | Comments Off on Senate Estimates point to possible MRFF clinical trial funding

$20bn investment into medical research – means what?

The Australian Government’s recent announcement of a AUD$20 billion Medical Research Future Fund (MRFF), the largest medical research fund in the world, has been something of a welcome surprise to the Australian medical research community. Australia has always been strong … Continue reading

Posted in Clinical Development, Federal Budget, Life Sciences Industry | Tagged , | Comments Off on $20bn investment into medical research – means what?

PharmaDispatch: Commercial Eyes working on ‘Convergence’

Commercial Eyes’ new Clinical Development division features in today’s issue of PharmaDispatch, reproduced here with the permission of www.pharmadispatch.com.au Commercial Eyes working on ‘Convergence’ According to the head of Commercial Eyes’ recently launched Clinical Development division, Ric DeGaris, his focus … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry | Tagged , | Comments Off on PharmaDispatch: Commercial Eyes working on ‘Convergence’

Commercial Eyes launches Clinical Development division

Commercial Eyes has announced the launch of a new Clinical Development offering, completing our suite of life sciences commercialisation services. Andrew Carter, Managing Director explains, ‘Our new Clinical Development Team will work closely with our Regulatory, Market Access and Medical … Continue reading

Posted in Clinical Development, Commercial Eyes | Comments Off on Commercial Eyes launches Clinical Development division

Top 5 – Reasons You Need a Consultant

There are many reasons you might need a consultant. And five of them add up to being T.I.R.E.D. This month’s Top 5 looks at how engaging a consultant can help you when you’re T.I.R.E.D – and the work still needs to be done. Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access, Medical Services, Regulatory Services | Tagged , | Comments Off on Top 5 – Reasons You Need a Consultant
Copyright © 2020 Commercial Eyes